StockData
Vaxcyte, Inc. logo

Vaxcyte, Inc. (PCVX) stock

PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$58.52−0.88 (-1.48%)

Close on Nov 18, 2026Market cap $8.71BP/E –Yield 0.00%

Vaxcyte free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vaxcyte's free cash flow for the twelve months ending Jun 30, 2026 was -$894.14M. For fiscal 2025 it was -$669.29M. The highest annual figure on record is -$32.24M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$669.29M–
FY2024Dec 31, 2024-$475.05M–
FY2023Dec 31, 2023-$312.85M–
FY2022Dec 31, 2022-$176.44M–
FY2021Dec 31, 2021-$127.95M–
FY2020Dec 31, 2020-$47.78M–
FY2019Dec 31, 2019-$48.34M–
FY2018Dec 31, 2018-$32.24M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$236.79M–
Q1 FY2026Mar 31, 2026-$282.73M–
Q4 FY2025Dec 31, 2025-$227.49M–
Q3 FY2025Sep 30, 2025-$147.13M–
Q2 FY2025Jun 30, 2025-$122.98M–
Q1 FY2025Mar 31, 2025-$171.70M–
Q4 FY2024Dec 31, 2024-$115.42M–
Q3 FY2024Sep 30, 2024-$65.66M–
Q2 FY2024Jun 30, 2024-$129.18M–
Q1 FY2024Mar 31, 2024-$164.80M–
Q4 FY2023Dec 31, 2023-$134.06M–
Q3 FY2023Sep 30, 2023-$64.89M–
Q2 FY2023Jun 30, 2023-$60.60M–
Q1 FY2023Mar 31, 2023-$53.30M–
Q4 FY2022Dec 31, 2022-$66.36M–
Q3 FY2022Sep 30, 2022-$39.39M–
Q2 FY2022Jun 30, 2022-$40.06M–
Q1 FY2022Mar 31, 2022-$30.62M–
Q4 FY2021Dec 31, 2021-$52.48M–
Q3 FY2021Sep 30, 2021-$30.13M–
Q2 FY2021Jun 30, 2021-$30.89M–
Q1 FY2021Mar 31, 2021-$14.45M–
Q4 FY2020Dec 31, 2020-$11.49M–
Q3 FY2020Sep 30, 2020-$13.08M–
Q2 FY2020Jun 30, 2020-$9.23M–
Q1 FY2020Mar 31, 2020-$13.98M–
Q4 FY2019Dec 31, 2019-$15.36M–
Q3 FY2019Sep 30, 2019-$9.52M–

More Vaxcyte figures

See a number that looks wrong?